New York, USA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Lennox-Gastaut Syndrome Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Players to Watch Out - Zogenix, Epygenix, SK Life Science, Takeda, Jazz Pharmaceuticals, Longboard Pharmaceuticals
The dynamics of the Lennox-Gastaut syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecast period (2023-2032).
DelveInsight’s Lennox-Gastaut Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Lennox-Gastaut syndrome emerging drugs, market share of individual therapies, and current and forecasted Lennox-Gastaut syndrome market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Lennox-Gastaut Syndrome Market Report
- As per DelveInsight’s analysis, the Lennox-Gastaut syndrome market size was found to be USD 596 million in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, In 2022, the total 7MM Lennox-Gastaut syndrome prevalent cases were 114K, which is expected to rise at a constant CAGR during the study period (2019-2032).
- Leading Lennox-Gastaut syndrome companies such as Zogenix, Inc., Epygenix, SK Life Science, Inc., Takeda, Jazz Pharmaceuticals, Longboard Pharmaceuticals, and others are developing novel Lennox-Gastaut syndrome drugs that can be available in the Lennox-Gastaut syndrome market in the coming years.
- Some of the key therapies for Lennox-Gastaut syndrome treatment include ZX008 (Fenfluramine Hydrochloride), Clemizole HCl, Carisbamate, Soticlestat, GWP42003-P, LP352, and others.
Discover which therapies are expected to grab the major Lennox-Gastaut syndrome market share @ Lennox-Gastaut Syndrome Market Report
Lennox-Gastaut Syndrome Overview
Lennox-Gastaut syndrome is a severe type of epilepsy that usually manifests in infancy or early childhood. Children with Lennox-Gastaut syndrome experience various seizure types, with atonic, tonic, and atypical absence seizures being the most common. The causes of Lennox-Gastaut syndrome can be broadly categorized into two groups: identifiable and cryptogenic causes. Identifiable causes encompass factors like brain injury, perinatal complications, congenital central nervous system abnormalities, infections, or metabolic disorders.
While EEG features play a pivotal role in the precise diagnosis of Lennox-Gastaut syndrome, it’s important to bear in mind that they may not manifest immediately, especially in young children. The SSW EEG pattern might not be detectable initially in patients transitioning from other epilepsy syndromes like West syndrome to Lennox-Gastaut syndrome. Consequently, when patients exhibit seizure types commonly linked to Lennox-Gastaut syndrome, especially tonic or atonic seizures, clinicians should remain vigilant about the potential for an Lennox-Gastaut syndrome diagnosis and actively monitor for EEG abnormalities to establish the diagnosis.
Lennox-Gastaut Syndrome Epidemiology Segmentation
The Lennox-Gastaut syndrome epidemiology section provides insights into the historical and current Lennox-Gastaut syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The Lennox-Gastaut syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Lennox-Gastaut Syndrome Prevalent Cases
- Total Lennox-Gastaut Syndrome Diagnosed Prevalent Cases
- Lennox-Gastaut Syndrome Gender-specific Diagnosed Prevalent Cases
- Lennox-Gastaut Syndrome Seizure-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Lennox-Gastaut syndrome epidemiology trends @ Lennox-Gastaut Syndrome Epidemiological Insights
Lennox-Gastaut Syndrome Treatment Market
Addressing Lennox-Gastaut syndrome can be challenging as there is no universally effective therapy. This condition often resists most treatment approaches, but three primary methods are employed: anti-epileptic drugs (AEDs), dietary interventions (such as the ketogenic diet), and surgical or device-based options (like VNS therapy or corpus callosotomy). In rare cases, resective surgery may be considered. Combining various AEDs is a common approach, although this can lead to significant side effects in high-dose, multi-drug regimens.
Valproate is often the initial treatment choice for individuals with Lennox-Gastaut syndrome due to its efficacy against various types of seizures. If valproate alone proves ineffective, additional medications like lamotrigine, topiramate, rufinamide, or clobazam may be considered. However, it’s important to note that valproate can lead to notable side effects, including tremors, decreased platelet count and function, and hyperammonemia.
The US Food and Drug Administration (FDA) has granted approval for a variety of drugs to treat Lennox-Gastaut syndrome, including Fenfluramine, Epidiolex, Topamax, Banzel, Lamictal, Felbatol, Onfi, and Klonopin. Interestingly, these drugs are not typically the first choice of treatment. Recently approved medications for this condition include Fintepla (Fenfluramine) and Banzel (Rufinamide). Fintepla, in particular, offers an alternative mechanism of action and has demonstrated the ability to significantly reduce the occurrence of seizures associated with drop attacks, a critical parameter for managing this severe form of epilepsy.
Learn more about the FDA-approved drugs for Lennox-Gastaut syndrome @ Drugs for Lennox-Gastaut Syndrome Treatment
Key Lennox-Gastaut Syndrome Therapies and Companies
- ZX008 (Fenfluramine Hydrochloride): Zogenix, Inc.
- Clemizole HCl: Epygenix
- Carisbamate: SK Life Science, Inc.
- Soticlestat: Takeda
- GWP42003-P: Jazz Pharmaceuticals
- LP352: Longboard Pharmaceuticals
To know more about Lennox-Gastaut syndrome clinical trials, visit @ Lennox-Gastaut Syndrome Treatment Drugs
Lennox-Gastaut Syndrome Market Dynamics
The dynamics of the Lennox-Gastaut syndrome market are expected to change in the coming years. Exploring alternative treatments involving off-label branded and generic prescription medications aimed at managing individual symptoms of Lennox-Gastaut syndrome. Moreover, there is a pressing demand for innovative therapeutic approaches to address the lack of effective and curative solutions for Lennox-Gastaut syndrome.
Furthermore, potential therapies are being investigated for the treatment of Lennox-Gastaut syndrome, and it is safe to predict that the treatment space will significantly impact the Lennox-Gastaut syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Lennox-Gastaut syndrome market in the 7MM.
However, several factors are impeding the growth of the Lennox-Gastaut syndrome market. This condition is a significantly impairing disorder that typically manifests between the ages of 3 and 5. Alongside the direct expenses associated with medical and related services, there are substantial financial and emotional burdens placed on families, including costs related to institutional and special education services.
Furthermore, the Lennox-Gastaut syndrome market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Lennox-Gastaut syndrome market growth.
| Lennox-Gastaut Syndrome Report Metrics | Details |
| Study Period | 2019–2032 |
| Lennox-Gastaut Syndrome Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Lennox-Gastaut Syndrome Market Size in 2022 | USD 596 Million |
| Key Lennox-Gastaut Syndrome Companies | Zogenix, Inc., Epygenix, SK Life Science, Inc., Takeda, Jazz Pharmaceuticals, Longboard Pharmaceuticals, and others |
| Key Lennox-Gastaut Syndrome Therapies | ZX008 (Fenfluramine Hydrochloride), Clemizole HCl, Carisbamate, Soticlestat, GWP42003-P, LP352, and others |
Scope of the Lennox-Gastaut Syndrome Market Report
- Therapeutic Assessment: Lennox-Gastaut Syndrome current marketed and emerging therapies
- Lennox-Gastaut Syndrome Market Dynamics: Attribute Analysis of Emerging Lennox-Gastaut Syndrome Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Lennox-Gastaut Syndrome Market Access and Reimbursement
Discover more about Lennox-Gastaut syndrome drugs in development @ Lennox-Gastaut Syndrome Clinical Trials
Table of Contents
| 1. | Lennox-Gastaut Syndrome Market Key Insights |
| 2. | Lennox-Gastaut Syndrome Market Report Introduction |
| 3. | Lennox-Gastaut Syndrome Market Overview at a Glance |
| 4. | Lennox-Gastaut Syndrome Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Lennox-Gastaut Syndrome Treatment and Management |
| 7. | Lennox-Gastaut Syndrome Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Lennox-Gastaut Syndrome Marketed Drugs |
| 10. | Lennox-Gastaut Syndrome Emerging Drugs |
| 11. | Seven Major Lennox-Gastaut Syndrome Market Analysis |
| 12. | Lennox-Gastaut Syndrome Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Lennox-Gastaut Syndrome Epidemiology Forecast
Lennox-Gastaut Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Lennox-Gastaut syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Lennox-Gastaut Syndrome Pipeline
Lennox-Gastaut Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Lennox-Gastaut syndrome companies, including Takeda, Marinus Pharmaceuticals, SK biopharmaceuticals, CuroNZ, TAHO Pharmaceuticals, Axium Pharmaceuticals, among others.
Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies including Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others.
Epilepsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epilepsy companies, including Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, among others.
Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory epilepsy companies including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.
Refractory Epilepsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory epilepsy companies, including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
